Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Net Cash Flow came in at -$9.0 million in Q1 2026, down 241.35% year-on-year from $6.3 million in Q1 2025, and down 163.35% quarter-over-quarter from $14.2 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$9.0 million for Q1 2026.
- On a quarterly basis, Net Cash Flow fell 241.35% year-over-year to -$9.0 million in Q1 2026; TTM through Mar 2026 was -$767000.0, a 123.72% decrease from a year earlier, with the FY2025 full-year figure at $14.6 million, up 792.48% from the prior year.
- Net Cash Flow fell to -$9.0 million in Q1 2026 per RANI's latest filing, from $14.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $14.2 million in Q4 2025 and bottomed at -$69.5 million in Q3 2022.
- The 5-year median for Net Cash Flow is -$2.4 million (2024), against an average of -$6.3 million.
- Biggest YoY gain for Net Cash Flow was 2850.68% in 2025; the steepest drop was 2477.64% in 2025.
- Year by year, Net Cash Flow stood at -$212000.0 in 2022, then soared by 520.75% to $892000.0 in 2023, then tumbled by 157.74% to -$515000.0 in 2024, then jumped by 2850.68% to $14.2 million in 2025, then tumbled by 163.35% to -$9.0 million in 2026.
- Per Business Quant, the three latest RANI Net Cash Flow figures stand at -$9.0 million (Q1 2026), $14.2 million (Q4 2025), and -$6.1 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | -8.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.97 Mn |
| Mar 31, 2026 | -8.97 Mn |
| Dec 31, 2025 | 14.17 Mn |
| Dec 31, 2025 | 14.17 Mn |
| Sep 30, 2025 | -6.11 Mn |
| Sep 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | 150,000.00 |
| Jun 30, 2025 | 150,000.00 |
| Mar 31, 2025 | 6.35 Mn |
| Mar 31, 2025 | 6.35 Mn |
| Dec 31, 2024 | -515,000.00 |
| Dec 31, 2024 | -515,000.00 |
| Sep 30, 2024 | -237,000.00 |
| Sep 30, 2024 | -237,000.00 |
| Jun 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.36 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | 892,000.00 |
| Dec 31, 2023 | 892,000.00 |